J.P. Morgan Notebook, Jan. 13: Drug Costs, Gilead, Valeant, Allergan/Actavis, Bristol
This article was originally published in The Pink Sheet Daily
Executive Summary
Welcome to “The Pink Sheet” DAILY’s round-up of news and notes from the 2015 J.P. Morgan Healthcare Conference in San Francisco. Pricing talk dominates day two, and companies weigh in on the fallout from failed M&A.
You may also be interested in...
J.P. Morgan Notebook, Jan. 14: AbbVie, AstraZeneca, Juno & Bluebird
Day three of “The Pink Sheet” DAILY’s round-up of news and notes from the 2015 J.P. Morgan Healthcare Conference in San Francisco. Pricing remains center stage, with AbbVie weighing in on HCV and AstraZeneca’s Soriot predicting cost-competition in oncology. CAR-T continues to advance, with updates from Juno and bluebird.
Ending “Buy-And-Bill” in Oncology: The Question is How, Not If
The public policy debate over affordability of cancer care is approaching consensus on the need to end the “buy-and-bill” model for chemotherapy. How, and how fast, are the key remaining questions. For biopharma manufacturers, there are good reasons to embrace the change.
With Winrevair Approved, Merck Has A Chance To Execute On CV Strategy
The activin signaling inhibitor sotatercept was approved by the US FDA for pulmonary arterial hypertension.